Clinical Trials 20 February 2026 - 9 March 2026

Xenon’s epilepsy drug posts strong Phase 3 data; XENE shares jump ahead of U.S. filing
···

Xenon’s epilepsy drug posts strong Phase 3 data; XENE shares jump ahead of U.S. filing

Xenon Pharmaceuticals said its Phase 3 trial showed azetukalner cut monthly focal onset seizures by 53.2% at the 25 mg dose versus 10.4% for placebo. Shares rose over 40% in premarket trading. The company plans to file for U.S. FDA approval in the third quarter of 2026. Dizziness was the most common side effect, with higher discontinuations in the 25 mg group.
March 9, 2026
Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3
···

Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3

Relmada Therapeutics will raise about $160 million in a private placement, priced at $4.75 a share, after reporting 12-month data showing a 76% complete response rate for NDV-01 in non-muscle invasive bladder cancer. The financing, expected to close by March 11, follows FDA feedback backing late-stage studies. NDV-01 showed no cases of disease progression or severe side effects among 25 patients at 12 months.
March 9, 2026
Grail stock halves after UK cancer trial miss; FDA and Medicare stakes rise
···

Grail stock halves after UK cancer trial miss; FDA and Medicare stakes rise

Grail shares fell about 50% to $50.21 in after-hours trading after its Galleri cancer blood test missed the main goal in a major UK trial. The study failed to show a statistically significant drop in late-stage cancers. Grail said it will release fuller data later this spring and extend trial follow-up. Investors are watching for U.S. regulatory and Medicare decisions.
February 20, 2026
Grail stock plunges almost 50% after NHS trial misses key goal for Galleri cancer test
···

Grail stock plunges almost 50% after NHS trial misses key goal for Galleri cancer test

Grail shares plunged 49.5% to $51.26 by midday Friday after its NHS-Galleri trial missed the primary endpoint of reducing stage III-IV cancers. The company said it would extend follow-up and submit results to ASCO. Over 10 million shares traded. Galleri’s FDA approval process continues, but analysts flagged uncertainty over insurance coverage.
February 20, 2026